India Alternatives Investment Advisors Ltd. invested up to USD 8 million for a significant minority stake in Brinton Pharmaceuticals Limited. Among the fastest growing companies in the Indian pharmaceutical market, Brinton is focused on dermatology and has recently expanded into the paediatric dermatology & respiratory segments.
Established in 2013, Brinton Pharmaceuticals is a speciality-focused pharmaceuticals company offering a range of branded dermatology and paediatric formulations. Through a specialized and dedicated field force of over 500 personnel, the company’s products are marketed in India and in 12 countries across emerging markets.
Speaking on the occasion, Mr. Rahulkumar Darda, Chairman & Managing Director, Brinton Pharmaceuticals said, “We are excited to partner with an investor of the calibre of India Alternatives and strongly believe this
association will bring synergies and help us continue our profitable growth journey. This investment will enhance our capabilities in formulations and Research & Development for niche areas of dermatology and cosmetology and support expansion of the company’s footprint within India as well as globally.”
Mr. Vijey Christopher J, Director, Brinton Pharmaceuticals added “In a short span of time Brinton has made its presence felt both in dermatology and paediatrics through our innovative high quality products stemming from
world-class R&D units across the globe. We are aiming for a leadership position in our represented product markets and have a strategic road-map to cross several milestones in the coming years.”
Commenting on the investment, Ms. Shivani Bhasin Sachdeva, Founder & CEO, India Alternatives said, “India Alternatives’ investment in Brinton reflects its recognition of the Company’s solid management team, differentiated brands and focus on niche therapeutic segments. The investment in Brinton fits very well with two of our themes of women oriented consumption and health & wellness. We are excited to partner with Rahul and his team to support them through the next leg of their journey.”
This transaction marks the second investment in Brinton by an institutional investor, following Tata Capital Healthcare Fund’s investment in 2017.
India Alternatives is a top performing mid-market private equity firm that backs unlisted companies that are the beneficiaries of transformational themes such as: women becoming more empowered as consumers; millennials driving a paradigm shift in consumption; technology reinventing financial services; and an increased focus on health and wellness. India Alternatives has made marquee investments including: NSDL – India’s largest depository; TransUnion CIBIL – a dominant credit information bureau; Gokaldas Intimatewear (Enamor) – a market leader in the women’s premium lingerie space and Seclore Technology – a rapidly growing cyber security company
Equirus Capital Private Limited acted as exclusive financial advisor to Brinton Pharmaceuticals, PDS Legal and Transaction Square acted as legal and tax advisors respectively to Brinton Pharmaceuticals. DSK Legal acted as legal advisors to India Alternatives.